NeoGenomics Inc (NEO)
Pretax margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -97,097 | -159,342 | -15,075 | -14,056 | 3,645 |
| Revenue | US$ in thousands | 601,638 | 508,222 | 479,247 | 436,029 | 404,099 |
| Pretax margin | -16.14% | -31.35% | -3.15% | -3.22% | 0.90% |
December 31, 2023 calculation
Pretax margin = EBT ÷ Revenue
= $-97,097K ÷ $601,638K
= -16.14%
Neogenomics Inc.'s pretax margin has shown variability in recent years. The company experienced a significant decrease in pretax margin from -3.16% in 2020 to -31.26% in 2022, indicating a period of financial challenges. However, there was a slight improvement in 2021 with a pretax margin of -3.11%. The most recent data for 2023 shows a further improvement, although still negative at -16.41%.
The negative pretax margins over the years suggest that the company has been struggling to generate profits before accounting for taxes. It is important for Neogenomics Inc. to closely monitor and address the factors contributing to these negative margins to enhance its financial performance and long-term sustainability.